Search Result

Results for "

lung ischemia-reperfusion injury

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (2) Annexin A (2) AP-1 (1) Apoptosis (8) Autophagy (4) CDK (2) Dynamin (1) Ferroptosis (2) FXR (2) Glutathione Peroxidase (2) Heme Oxygenase (HO) (2) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Interleukin Related (2) Keap1-Nrf2 (5) MMP (2) NADPH Oxidase (1) NF-κB (7) NO Synthase (1) NOD-like Receptor (NLR) (4) p38 MAPK (1) PARP (4) Phospholipase (1) Pyroptosis (2) Reactive Oxygen Species (ROS) (6) Reference Standards (3) Sirtuin (2) Syk (2) TGF-β Receptor (2) TREM receptor (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (9) Inflammation/Immunology (11) Metabolic Disease (4) Neurological Disease (1)

By Targets:

Akt (1)

AMPK (2)

Annexin A (2)

AP-1 (1)

Apoptosis (8)

Autophagy (4)

CDK (2)

Dynamin (1)

Ferroptosis (2)

FXR (2)

Glutathione Peroxidase (2)

Heme Oxygenase (HO) (2)

IKK (1)

Indoleamine 2,3-Dioxygenase (IDO) (2)

Interleukin Related (2)

Keap1-Nrf2 (5)

MMP (2)

NADPH Oxidase (1)

NF-κB (7)

NO Synthase (1)

NOD-like Receptor (NLR) (4)

p38 MAPK (1)

PARP (4)

Phospholipase (1)

Pyroptosis (2)

Reactive Oxygen Species (ROS) (6)

Reference Standards (3)

Sirtuin (2)

Syk (2)

TGF-β Receptor (2)

TREM receptor (2)

By Research Areas:

Cancer (7)

Cardiovascular Disease (9)

Inflammation/Immunology (11)

Metabolic Disease (4)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3211

Nangibotide 4 Publications Verification LR12	TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Inflammation/Immunology
Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .

HY-P1098

Ac2-26 Maximum Cited Publications 7 Publications Verification	Annexin A NF-κB	Inflammation/Immunology
Ac2-26 is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-P1098A

Ac2-26 TFA Maximum Cited Publications 7 Publications Verification	Annexin A NF-κB	Inflammation/Immunology
Ac2-26 TFA is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-P3211A

Nangibotide TFA 4 Publications Verification LR12 TFA	TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis	Cardiovascular Disease Inflammation/Immunology
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .

HY-P1098B

Ac2-26 ammonium Maximum Cited Publications 7 Publications Verification	IKK	Inflammation/Immunology
Ac2-26 ammonium is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 ammonium induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ammonium ameliorates lung ischemia-reperfusion injury. Ac2-26 ammonium also inhibits airway inflammation and hyperresponsiveness in an asthma rat model .

HY-161119

Drpitor1a	Dynamin Reactive Oxygen Species (ROS)	Cardiovascular Disease Cancer
Drpitor1a is a potent Drp1 inhibitor. Drpitor1a inhibits mitochondrial ROS production, preventes mitochondrial fission, and improves right ventricular diastolic dysfunction during IR (ischemia reperfusion) injury. Drpitor1a has the potential for the research of lung cancer ^[1]

HY-N0806

Sweroside 2 Publications Verification	Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .

HY-N0805

Alisol B 23-acetate 2 Publications Verification 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate	Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

HY-106162A

ONO-1714	NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ONO-1714 is an orally active nitric oxide synthase inhibitor. ONO-1714 attenuates endotoxin-induced acute lung injury, reduces intestinal ischemia–reperfusion injury, represses biliary carcinogenesis .

HY-168065

Keap1-Nrf2-IN-22	Keap1-Nrf2	Inflammation/Immunology
Keap1-Nrf2-IN-22 (compound 19) is a Keap1-Nrf2 inhibitor， with a K_D2 value of 42.2 nM for Keap1. Keap1-Nrf2-IN-22 can be used for the study of acute lung injury (ALI) and cerebral ischemia/reperfusion (I/R) injury .

HY-N0806R

Sweroside (Standard)	Reference Standards Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP	Metabolic Disease
Sweroside (Standard) is the analytical standard of Sweroside (HY-N0806). This product is intended for research and analytical applications. Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .

HY-N0805R

Alisol B 23-acetate (Standard) 23-Acetylalismol B (Standard); 23-O-Acetylalisol B (Standard); Alisol B monoacetate (Standard)	Reference Standards Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

HY-N0353R

Curdione (Standard) (+)-Curdione (Standard)	Reference Standards Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)	Others
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression .

HY-N0353

Curdione 1 Publications Verification (+)-Curdione	Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)	Cardiovascular Disease Neurological Disease Cancer
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression .

HY-136271

MJ33	Phospholipase NADPH Oxidase p38 MAPK Akt NF-κB AP-1 Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Cancer
MJ-33 is a competitive phospholipase A₂ (PLA₂) inhibitor. MJ-33 inhibits the activation of NOX2 by blocking the PLA₂ activity of Prdx6, thereby reducing the production of ROS. MJ-33 effectively inhibits the activity of acidic PLA₂ (pH 4.0), reduces the degradation of pulmonary surfactant phosphatidylcholine (PC), but has no effect on alkaline PLA₂ (pH 8.5). MJ-33 significantly alleviates lung oxidative damage induced by ischemia-reperfusion (I/R). MJ-33 significantly inhibits the invasive, migratory and adhesive abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 can be used to study ROS-related diseases and prostate cancer .

Cat. No.	Product Name	Target	Research Area